Clinical Trial Update: Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets

View source ↗

Summary

AstraZeneca-sponsored clinical trial update reports the percentage of secondary prevention patients who achieved their LDL-C targets in the study. The update fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Carotid Artery Stenosis
• Coronary Artery Disease
• Diabetes Mellitus
• Hyperlipidemia
• Peripheral Vascular Disease

Snippet

Sponsor: AstraZeneca | Conditions: Hyperlipidemias, Atherosclerosis | Status: COMPLETED